Full-Time

AI Data Scientist

Updated on 9/12/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Bachelor's, Master's

Category
Software Engineering (1)
Required Skills
LLM
Python
Data Science
Neural Networks
SQL
Machine Learning
AWS
Databricks
Product Design

Get referred to Amgen

See people who can refer or advise you

Requirements
  • A Master's or Bachelor's degree in Data Science, Artificial Intelligence, Computer Science, Information Science, or a related field, plus 4 to 7 years of experience.
  • Strong hands-on experience in Generative AI, large language models, and agentic AI concepts and applications.
  • Proficiency in Python for rapid prototyping, solution development, and scaling AI-driven capabilities.
  • Strong working knowledge of SQL for data analysis, transformation, and integration across enterprise systems.
  • Experience with AWS cloud services and well-architected cloud design best practices, including AWS Bedrock.
  • Experience using OpenAI APIs and related AI development patterns for enterprise solutions.
  • Hands-on experience with Databricks or comparable data and AI platforms.
  • Strong understanding of integrated data, enterprise data ecosystems, and data-centric solution design.
  • Experience with knowledge graph and graph-based data platforms such as Stardog, GraphDB, or similar technologies.
  • Strong understanding of FAIR data principles and their application in enterprise and pharmaceutical data environments.
  • Ability to translate business concepts and requirements into scalable AI, semantic, and data solutions.
  • Strong analytical thinking and structured problem-solving skills, especially in complex and regulated environments.
  • Ability to manage ambiguity, think strategically, and convert emerging opportunities into practical solutions.
  • Ability to prioritize and manage multiple initiatives in a dynamic setting.
  • Ability to influence without authority and build alignment across technical and business stakeholders.
  • Ability to independently drive high-impact work from concept through implementation.
Responsibilities
  • Design, develop, and deploy AI solutions using Generative AI, large language models, and agentic AI patterns to address high-value business and operational challenges.
  • Build intelligent solutions that combine structured and unstructured data, semantic data models, and knowledge graph capabilities to improve automation, search, insight generation, and decision support.
  • Develop and scale proof-of-concept solutions in Python and transition them into robust, enterprise-ready AI products for broader organizational use.
  • Apply SQL and other data transformation techniques to analyze, integrate, and prepare data from multiple enterprise sources.
  • Collaborate with business stakeholders, product teams, data engineers, architects, and domain experts to identify AI use cases and translate business requirements into scalable technical solutions.
  • Integrate FAIR data principles and data-centric design practices with AI to promote interoperability, discoverability, and governance of data assets.
  • Leverage AWS services and cloud best practices, including AWS Bedrock, to design scalable, secure, and maintainable AI solutions.
  • Develop AI-enabled applications using OpenAI APIs, foundation model platforms, and enterprise AI tooling in alignment with business and technical standards.
  • Utilize Databricks and associated data and AI workflows to support experimentation, model development, and scalable deployment patterns.
  • Ensure alignment with Responsible AI, security, privacy, and compliance expectations, including emerging AI regulatory frameworks such as the EU AI Act.
  • Facilitate working sessions with stakeholders to clarify concepts, define success criteria, and align on transformation opportunities enabled by AI.
  • Contribute to the development of standards, reusable assets, and best practices for AI solution design, semantic modeling, and product scaling.
  • Promote continuous improvement, innovation, and transformation by identifying opportunities to improve current processes, technologies, and ways of working.
  • Stay current with advancements in AI, agentic architectures, and regulatory expectations, and apply those insights pragmatically within the organization.
Desired Qualifications
  • Experience with regulatory data, regulatory submission processes, or compliance requirements in the pharmaceutical domain.
  • Familiarity with the pharmaceutical lifecycle of data, including development, manufacturing, regulatory, and operational domains.
  • Knowledge of machine learning and deep learning concepts, especially where they complement Generative AI use cases.
  • Experience integrating data from clinical, laboratory, manufacturing, quality, or regulatory systems.
  • Familiarity with healthcare and life sciences standards such as FHIR, IDMP, or related interoperability frameworks.
  • Exposure to structured content management, content automation, or AI-enabled document workflows.
  • Experience supporting AI solutions in highly regulated environments with strong governance expectations.
  • Familiarity with product-oriented delivery and scaling AI proofs of concept into operationalized enterprise capabilities.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 10% to $10.1 billion, and guidance increased to $38.2 billion-$39.4 billion.
  • Repatha sales jumped 37% to $953 million in Q2 2026, with U.S. prescriptions up 50%.
  • MariTide advanced through multiple Phase 3 studies in 2026, supporting a 2027 obesity catalyst.

What critics are saying

  • Prolia sales fell 32% in Q2 2026 as biosimilars attack Amgen’s legacy cash cow.
  • FDA proposed withdrawing Tavneos in April 2026, signaling regulatory risk from integrity and efficacy issues.
  • Olpasiran now faces Novartis pelacarsen failure scrutiny; a negative 2028 OCEAN(a) readout would crush Lp(a) upside.

What makes Amgen unique

  • Repatha, Evenity, and Uplizna diversify Amgen beyond one blockbuster, per August 2026 sales.
  • MariTide targets quarterly or eight-week dosing, unlike Lilly and Novo Nordisk weekly injections.
  • Amgen’s 2027 Hyderabad Science and Innovation Center expands AI-enabled drug discovery globally.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Sep 10th, 2026
Amgen trades at 17x 2026 earnings, but forecast margin expansion assumes MariTide success

Amgen trades at $393 per share, representing a trailing multiple of 23.3 times adjusted earnings. The biotech faces declining sales from Prolia and XGEVA, down 33% year-over-year to $1.1 billion in Q2 2026, due to biosimilar competition. Six key growth medicines grew 26% year-over-year, accounting for nearly 70% of Q2 product sales. Analysts forecast the forward multiple at 17.0 times for fiscal 2026 and 16.1 times for 2027. However, consensus assumes expanding profit margins whilst Amgen increases spending. Non-GAAP research spending is set to grow in high single digits for 2026, funding nine Phase III trials for MariTide, its obesity treatment candidate. Management warned of meaningful operating expense increases in Q3 2026. The valuation depends on margin expansion materialising during this investment phase.

Yahoo Finance
Sep 7th, 2026
Amgen's $437 olpasiran bet faces higher bar after Novartis Lp(a) drug fails Phase 3 trial

Amgen faces heightened scrutiny for its experimental heart drug olpasiran after rival Novartis's pelacarsen failed to reduce major cardiovascular events in a Phase 3 trial, despite successfully lowering lipoprotein(a) levels. The setback demonstrates that improving laboratory biomarkers may not translate to better patient outcomes. Amgen's OCEAN(a) outcomes study has enrolled 7,297 participants and is tracking heart-related deaths and procedures over roughly five years. While olpasiran uses a different design and may target different patients, pelacarsen's failure removes assumptions about the commercial value of lowering Lp(a). Amgen's shares traded at $437.23, sitting 19.54% above its estimated fair value of $365.76. The company reported $10.1 billion in second-quarter revenue and $3.5 billion in free cash flow.

Yahoo Finance
Sep 1st, 2026
Amgen's Repatha hits $953M in Q2 sales, up 37% as Cramer calls it "biggest market of all time

Jim Cramer highlighted Amgen's cholesterol drug Repatha as a key driver behind the company's 31% year-to-date rally, calling it an overlooked catalyst by Wall Street. The injectable treatment, administered every two weeks, reduces death risk by 20% in patients at high risk for heart attack or stroke. Repatha generated $953 million in second-quarter sales, up 37% year-over-year. US new prescriptions surged over 50%, split evenly between cardiologist use and primary-care adoption for high-risk patients. Cramer noted the drug works against diabetes and high cholesterol, though insurance reimbursement has posed challenges. Amgen trades at a forward PE of 19, compared to Eli Lilly's 32, whilst outperforming Lilly's 10% gain this year. Repatha is one of six growth drivers representing nearly 70% of Amgen's product sales. The company raised full-year revenue guidance to $38.2-$39.4 billion.

Yahoo Finance
Aug 19th, 2026
Amgen surges 3.5% to $440 as healthcare stocks hit record high on strong Q2 results

Amgen shares jumped 3.5% to $440.08 on Wednesday as healthcare stocks reached record highs. The biotech company reported second-quarter revenue of $10.1 billion, up 10%, whilst GAAP earnings surged 65% to $4.37 per share. Twenty-two of Amgen's medicines posted double-digit sales growth, with seventeen products generating over $1 billion in annualised sales. Six key growth products climbed 26% and now account for nearly 70% of product revenue. The rally came as investors rotated into healthcare following excitement around Merck and Moderna's melanoma breakthrough. However, Amgen now trades at a 19% premium to its fair value estimate of $365.04, putting pressure on execution as some products like Prolia face headwinds.

Yahoo Finance
Aug 14th, 2026
Amgen and Regeneron emerge as GLP-1 investment alternatives beyond Eli Lilly and Novo Nordisk

Amgen and Regeneron could benefit from surging demand for GLP-1 drugs, which traditionally treated diabetes but now address obesity and obstructive sleep apnea. Amgen's stock is up 27% this year, with second-quarter revenue rising 10% year-over-year to $10.1 billion. The company is testing MariTide, an investigational GLP-1 medicine, in phase 3 studies for weight management and diabetes. MariTide could be administered monthly or less frequently, offering a convenience advantage over current daily or weekly treatments. Regeneron is also positioned to capitalise on the GLP-1 market expansion. Both companies present alternatives to current market leaders Eli Lilly and Novo Nordisk for investors seeking exposure to the growing GLP-1 drug category.